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Summary
In contrast to primary hypogonadism, whereby the
rise of gonadotropin levels helps establishing a di-
agnosis, the diagnosis of secondary hypogo-
nadism relies for the most part, on the identifica-
tion of a low testosterone level in the right clinical
context. Establishing that a patient indeed has a
low testosterone level requires taking into account
several physiological as well analytical aspects.
The vast majority of testosterone in men circulates
in plasma bound to albumin (50%), sex-steroid
binding globulin (SHBG) (44%) and other proteins
(4%), while only 2% is found free. The biologically
active fraction consists of the free and the albu-
min-bound fractions. Testosterone levels are high-
est in the early morning and lowest during the
summer. Both total and free testosterone decline
with age, as SHBG levels increase. Conditions
such as obesity and diabetes also result in dimin-
ished testosterone concentrations, while they are
accompanied by low SHBG levels. Currently, meas-
urement of total testosterone in hospital laborato-
ries is usually performed on fully automated im-
munoassay analyzers. Although tandem mass
spectrometry methods after gas or liquid chro-
matography are the most accurate means for
testosterone measurement, they are still not wide-
ly available in most clinical laboratories. In some
cases the concentration of total testosterone may
not always represent a true reflection of the patient
androgen status and therefore an estimate of the
non-SHBG or bioavailable fraction may be a more
appropriate measure. Methods of assessment of
the non-SHBG-bound fraction of testosterone in-
clude estimation of the free concentration by meth-
ods including the calculation of the free androgen
index (FAI), equilibrium dialysis, centrifugal ultra-
filtration, direct analog RIA or calculation of the
free fraction.
KEY WORDS:  testosterone; free testosterone; SHBG;
hypogonadism.
Introduction
Testosterone is the main androgen synthesized and
secreted by the normal adult male testicle (1,2). The
regulation of the gonadal axis begins at hypothalamic
nuclei where highly specialized neurons “awake” dur-
ing puberty and start synthesizing and releasing GnRH
(Gonadotrophin releasing hormone) in a pulsatile man-
ner, although higher brain nuclei and sites including the
neocortex, also play an important role (1,2) (Fig. 1).
GnRH acts through specific Gs-protein coupled mem-
brane receptors on the gonadotroph cells of the anteri-
or pituitary, resulting in the transcription of the genes
that encode the specific beta subunits of LH and FSH
as well as the common alpha subunit, and subsequent-
ly in the secretion of these gonadotropins into the sys-
temic circulation (1,2) (Fig. 1). LH exerts its biological
effects, stimulating the testosterone-producing Leydig
cells, whereas FSH targets the Sertoli cells and is
more involved in spermatogenesis as well as in the
synthesis and secretion of inhibin (1,2) (Fig. 1). The
testosterone secreted by the testicle, in turn, inhibits
the release of LH and FSH via a negative feedback
loop at both the hypothalamic and pituitary levels,
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Figure 1 - Regulation of the male hypothalamic-pituitary-
testicular axis.
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whereas inhibin acts only at the pituitary level (1,2)
(Fig. 1). Irrespective of the etiology, in primary hypog-
onadism the loss of testosterone negative feedback re-
sults in a significant increment in gonadotropin secre-
tion (1,2) (Tab. 1). In contrast, gonadal failure or insuf-
ficiency resulting from pituitary or hypothalamic causes
is associated with low or inappropriately normal serum
concentrations of LH and FSH (1,2) (Tab. 2). Thus
whereas the diagnosis of primary hypogonadism is fa-
cilitated by the finding of high gonadotrophins in blood,
the biochemical diagnosis of secondary hypogonadism
relies only on the measurement of serum testosterone
in the appropriate clinical context.  Establishing that a
patient has a low testosterone level is not always an
easy task since several physiological and analytical as-
pects need to be taken into consideration. The purpose
of this review is to summarize such aspects.
Basic physiology and biochemistry of circulating
testosterone in men
The vast majority of testosterone in the adult male cir-
culates in plasma bound to albumin (50%) and sex hor-
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mone binding globulin (SHBG, 44%), while only 2% is
found free (3,4). The biologically active fraction con-
sists of the free and the albumin-bound fractions (3,4).
The precise role of these specific binding proteins re-
mains incompletely understood. However, SHBG in
particular appears to actively participate in the trans-
port of testosterone into target tissues like the prostate
and the testes themselves (5). Like with other steroid
hormones such as estradiol and cortisol, the rise in
binding proteins is associated with a concomitant in-
crement in the measured total testosterone concentra-
tions (3,4).
Testosterone secretion follows a circadian rhythm with
the highest level found in the morning and the lowest in
the evening (6). Such diurnal variation is clearly seen
in males up to the seventh decade and appears to be
distorted thereafter (6). The existence of a seasonal
variation is controversial but it has been suggested that
testosterone concentrations are higher during the win-
ter and lower during the summer (6). Testosterone lev-
els decrease progressively from early adulthood to old-
er age (7-9).  This is particularly true for free testos-
terone as SHBG concentrations rise with advancing
age (7-9). The decline of testosterone with age is pro-
foundly influenced by adiposity and the concomitant in-
creased prevalence of conditions like diabetes that are
also associated with low androgen concentrations (7-
9). In contrast to menopause in women, andropause in
men is more of a continuous age-dependent process
with high inter-individual variability and overlapping
serum testosterone concentrations between age
groups (7-9). Serum concentrations of total testos-
terone are lower in obese men and this is for the most
part due to a concomitant reduction in SHBG levels (7).
Acute illness, HIV infection and malnutrition are asso-
ciated with low total and free testosterone concentra-
tions due to an adaptive state of secondary hypogo-
nadism (7).
Analytical aspects of testosterone measurement
Total testosterone:
Testosterone measurement methods suffer from a lack
of age- and gender-adjusted normal ranges and a uni-
versally recognized calibrating standard (10). Most
clinical laboratories measure total testosterone (pro-
tein-bound plus free testosterone) by fully automated
immunoassay analyzers (7,10,11). Prior to immunoas-
say, binding proteins need to be displaced from testos-
terone, be it by extraction of the steroid into an organ-
ic solvent or by the addition of a chemical agent with a
higher affinity for the binding protein (7,10,11). The
concentration of total testosterone in normal healthy
men is at least four times higher than in normal adult
women, and in most laboratories the quoted normal
reference values range from 11 to 35 nmol/L (7,10,11).
Compared to the original “manual” RIA, the currently
in-use immunoassay platforms are capable of measur-
ing many samples at the same time and allow for a
quick turn-around of results (7,10,11). Inter-assay coef-
ficients of variation among total testosterone im-
Congenital
• Klinefelter Syndrome
• FSH/ILH receptor 
mutations
• Varicocele
• Cryptorchidism
• Disorders of androgen
synthesis
• Myotonic dystrophy
• Acquired
Acquired
• Mump·s and other 
infections
• XRT and alkylating agents
• Ketoconazole
• Glucocorticoids
• Environmental toxins
• Trauma
• Testicular torsion
• Autoimmune
• Hepatic & renal failure
• HIV
Table 1 - Etiology of primary male hypogonadism.
Primary Male hypogonadism
Congenital
• Kallman syndrome
• DAXl and GPR54 
mutations
• Leptin and leptin rec. mut.
• Prader-Willy syndrome
• Gonadotropin SU 
mutations
• Pituitary cytodifferentiation
abnormalities
Acquired
• Suppression of 
gonadotropins
- Hyperprolactinemia
- Gonadal steroids 
glucorticoid adm.
- Opiates & GnRH analogs
- Critical illness
- Chronic systemic 
disease & DM
• Gonadotrope damage
- Pituitary adenomas
- Craneopharyngiomas
- Pituitary mets
- Pituitary apoplexy
- Trauma
- Surgery and XRT to the
sellar region
Table 2 - Etiology of secondary male hypogonadism.
Secondary Male Hypogonadism
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munoassays range from 2 to 8% (7,10,11). The main
cross-reactant in testosterone assays is 5-alpha-dihy-
drotestosterone (DHT), which can still be detected af-
ter solvent extraction.  However, the normal concentra-
tions of serum DHT are considerably lower than those
of testosterone and are rarely elevated enough to sig-
nificantly interfere with testosterone measurement (7).
Abnormally high testosterone concentrations (>40
nmol/L) are usually only found in patients receiving re-
placement therapy, since testosterone-secreting tu-
mors are very rare. Spuriously low testosterone con-
centrations due to analytical causes are also very infre-
quent but can be found when the binding proteins in
the sample are not properly extracted or even more
rarely, by autoantibodies that recognize the labeled
antigen (7,10,11).
Direct immunoassays without prior extraction for bind-
ing proteins tend to overestimate testosterone levels
and have limited accuracy at concentrations below 11
nmol/L (7,10,11). Although these direct assays are cur-
rently fully automated and provide a rapid turnaround
time, they are susceptible to matrix effects and the ref-
erence intervals are not standardized and totally
method-dependent (7,10,11). RIA after chromatogra-
phy extraction has been extensively used and there
are well-documented reference intervals in different
populations, however, it is technically cumbersome
and very few clinical laboratories are qualified to do it
(7,10,11). Mass spectrometry (MS) after extraction with
either liquid or gas chromatography is highly accurate
when properly validated and allows measurement of
multiple steroids in the same aliquot, based on their
chemical structures; tandem MS can increase the
specificity of the method (12,13). The drawbacks of MS
are their relatively high cost, lack of standardization
and limited throughput (10).  
Free testosterone:
As mentioned before, less than 2% of circulating
testosterone is found free in plasma; the term bioavail-
able testosterone refers to the free and albumin-bound
fractions, and appears to be biologically active. The
reference methods for measuring free testosterone are
equilibrium dialysis and centrifugal ultrafiltration
(14,15). Both of these methodologies are technically
cumbersome and thus, not widely available in clinical
laboratories. Free testosterone is measured at many
hospital laboratories by means of a tracer analog tech-
nique or direct RIA, which are rather inaccurate and
non-validated (10). Bioavailable testosterone is meas-
ured in reference laboratories by the ammonium sul-
fate precipitation technique, which is also technically
difficult (16).
Methods for estimating free testosterone:
In view of the difficulties in measuring free testosterone
by robust and reliable methods such as equilibrium
dialysis, several equations have been developed to es-
timate the percent of free testosterone in serum.  Be-
sides the total testosterone concentration, these for-
mulae require the accurate measurement of SHBG
concentrations, which can be done by immunoassays.
The simplest of these equations calculates the free an-
drogen index (FAI) as follows: FAI=[Total testosterone]
x 100/[SHBG].
The FAI is useful in the diagnosis of hyperandrogenism
in women but is not very reliable in discriminating hy-
pogonadal from normal men (7). Another, more accu-
rate way of calculating free testosterone based on the
law of mass action also uses the measured total
testosterone, SHBG and albumin but includes in the
equation the dissociation constants (Kd) for testos-
terone with SHBG and with albumin (14,17). This
method correlates very well with free testosterone
measured by equilibrium dialysis (14, 17). These and
other algorithms for the calculation of free and bioavail-
able testosterone are available at the website of the In-
ternational Society for the Study of the Ageing Male
(www.issam.ch).
Prevalence of androgen deficiency in men
Late-onset hypogonadism is a clinical and biochemical
state with advancing age, characterized by particular
symptoms and a low testosterone level (10). The exact
prevalence and incidence of this syndrome in men is
not known, as most of the published epidemiological
studies used poorly validated immunoassay measure-
ments of total testosterone (10). Such studies have
used different definitions of hypogonadism based on
the presence of symptoms, but the majority simply re-
ports the prevalence of low testosterone levels (8,10).
Thus, the precise testosterone level below which,
symptoms of androgen deficiency emerge and adverse
health outcomes ensue remains unclear.
Relatively recent publications of the European Male
Aging Study (EMAS) provide a reasonable approxima-
tion to solving this issue (18-20). The EMAS has ana-
lyzed data from almost 4000 middle age and elderly
men, recruited at 8 European centers (18-20).  A cross-
sectional analysis of over 3000 men spanning 4
decades of age from 40 to 80 years old found a decline
in total and free testosterone concentrations of 8.6%
and 33.1%, respectively, along with a 47% rise in
SHBG levels (18). In this study, multiple factors alter-
ing the gonadotropic axis, such as obesity, smoking
and the presence of co-morbidities like diabetes, are
superimposed on the progressive testicular impairment
associated with age (18). More recent reports from the
same group, linked specific total testosterone-meas-
ured by GC-MS/MS-and calculated free testosterone
levels with the appearance of symptoms of androgen
deficiency (19,20). A decrease frequency of sexual
thoughts, erectile dysfunction, a decreased frequency
of morning erections and a reduced vigor were associ-
ated with total testosterone thresholds of 8, 8.5, 11 and
13 nmol/L, respectively; free testosterone levels of 160
pmol/L, were associated with a decreased frequency of
sexual thoughts, whereas erectile dysfunction and de-
creased frequency of morning erections were linked to
a free testosterone level of 280 pmol/L (19-20).  Inter-
estingly, psychological symptoms were not associated
with a particular testosterone threshold. In this cohort,
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4.1% and 17% of the population had total testosterone
levels below 8 and 11 nmol/L, respectively (19,20).
Overall, the prevalence of late-onset hypogonadism was
estimated to be 2.1%, ranging from 0.1% in men aged
40-49 years, to 5.1% in men aged 70-79 years (19,20).
Data from the Massachusetts Male Aging Study indicate
that the prevalence of symptomatic androgen deficiency
is between 6 and 12% (21,22). A similar figure has been
reported in a population-based study derived from the
Boston Area Community Health Survey and including
Black, Hispanic and White men (23).  
Another aspect that needs to be considered is the type
of population studied, since the prevalence of andro-
gen deficiency seems to be higher among men attend-
ing a primary care facility than among community-
dwelling individuals (24,25). The Hypogonadism in
Males Study estimated the prevalence of clinical and
biochemical androgen deficiency in over 2000 men
aged more than 45 years, visiting primary care prac-
tices in the United States (24). In this study, the preva-
lence of hypogonadism was close to 40%; conditions
such as diabetes, hypertension, obesity, dyslipidemia
and obstructive pulmonary disease, significantly in-
creased the likelihood of androgen deficiency with
odds ratios that ranged from 1.5 to 2.4 (24). Androgen
deficiency is considerably more common in patients
with diabetes. Biswass et al., have recently evaluated
115 subjects with type 2 and 93 with type 1 diabetes
and compared them to an age-matched control group
(26). These authors found that 45% and 61% of their
patients with type 2 diabetes had very low levels of to-
tal (<11.9 nmol/L) and free testosterone (<260 pmol/L),
respectively (26). The prevalence of a low androgen
level was considerably lower among patients with type
1 diabetes, yet still significantly higher that in the con-
trol population (26). The frequency of low total and free
testosterone in this study was strongly affected by age
and central adiposity yet, androgen levels correlated
rather weakly symptoms of sexual dysfunction and di-
abetes-related quality of life (26).
Concluding remarks
• Establishing the diagnosis of androgen deficiency
in adult males can be a difficult task due to both
physiological and analytical complexities of testos-
terone measurement.
• The initial hormonal evaluation of a man with prob-
able hypogonadism should include measurement
of early morning total testosterone, as well as LH,
FSH and prolactin in order to differentiate primary
from secondary hypogonadism. SHBG levels
should also be measured in order to be able to es-
timate free testosterone levels.
• Ideally, total testosterone should be measured by
tandem MS after extraction by either gas or liquid
chromatography. Alternative methods include auto-
mated immunoassays that use an extraction step.
• A total testosterone value below 8 nmol/L is indica-
tive of androgen deficiency and correlates well with
the presence of symptoms. In subjects with values
between 8 and 11 mmol/L, the free testosterone
level is helpful in establishing a diagnosis.
• The prevalence of androgen deficiency among ag-
ing males varies according to the type of population
studied. Among community dwelling populations it
is reported to be between 6 and 12%, whereas
among patients attending primary care facilities it
can be as high as 30-40%.
• Normal aging is associated with a decline in testos-
terone levels, particularly in the free fraction, but
symptoms of androgen deficiency such as sexual
dysfunction do not always correlate with hormonal
data.
• Conditions such as diabetes, obesity and insulin
resistance are also associated with a reduced con-
centration of testosterone.
• The evaluation of the androgen status should be al-
ways carried out considering the clinical context.
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